Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 606 JPY -0.12% Market Closed
Market Cap: 754.2B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note

Operating Margin
Ono Pharmaceutical Co Ltd

24.5%
Current
31%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.5%
=
Operating Profit
118.8B
/
Revenue
484.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
Ono Pharmaceutical Co Ltd
TSE:4528
754.4B JPY
25%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
28%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
34%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
21%
CH
Novartis AG
SIX:NOVN
169.7B CHF
31%
US
Pfizer Inc
NYSE:PFE
149.4B USD
22%
Country JP
Market Cap 754.4B JPY
Operating Margin
25%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.6T DKK
Operating Margin
44%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Country CH
Market Cap 197.2B CHF
Operating Margin
32%
Country UK
Market Cap 159B GBP
Operating Margin
21%
Country CH
Market Cap 169.7B CHF
Operating Margin
31%
Country US
Market Cap 149.4B USD
Operating Margin
22%
No Stocks Found

Ono Pharmaceutical Co Ltd
Glance View

Market Cap
754.4B JPY
Industry
Pharmaceuticals

In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.

Intrinsic Value
2 699.78 JPY
Undervaluation 41%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.5%
=
Operating Profit
118.8B
/
Revenue
484.3B
What is the Operating Margin of Ono Pharmaceutical Co Ltd?

Based on Ono Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 24.5%.